Horus Pharma is a French laboratory, founded in 2003. Independent and family-owned company, we are focused on ophthalmology, acting in several countries across Europe. The Horus Pharma group is directly present in Spain, Belgium, the Netherlands, Luxembourg, and Switzerland. Our portfolio is also available in Italy, the UK, Germany, and Morocco, thanks to our key partners. Our key strength is innovation related to a high-performing R&D policy. We are covering all the therapeutic segments including glaucoma, retina, and cornea. Acting both in pharmaceutical and surgical markets, we are a pioneer in the preservative-free culture. As a patient-oriented company, we strongly believe that the future relies not only on the strength of our innovative products, but also on the digitalization of our company, allowing us to bring service to the industry. Patient-oriented, Horus Pharma is bringing broad, consistent, and innovative products and services to the European market.
Chengdu Kanghong Pharmaceutical Group Co., Ltd. is dedicated to improving ophthalmic care through the development and commercialization of innovative products for a wide range of ocular conditions. Founded in 1996, the Group became a publicly listed company in China in 2015 and acquired IOPtima, a company in Israel dedicated to the development of ophthalmic devices.
About Conbercept Conbercept is a new generation anti-VEGF, a 100 percent humanized fusion protein that targets VEGF-B, placental growth factor, and various isoforms of VEGF-A. Conbercept has been approved and marketed in China as Lumitin®, for the treatment of retina diseases. In China, Conbercept was approved for the treatment of nAMD in 2014, for the treatment of pathological myopia associated with choroidal neovascularization (“pmCNV") in 2017, and for the treatment of diabetic macular edema (“DME") in 2019. A large number of real-world treatment and investigator-sponsored trials have shown conbercept to be safe and efficacious.